Derma specialist Maruho has taken steps to recharge its pipeline through deals with fellow Japanese firms for two novel assets.
Mid-sized dermatology specialist Maruho Co. Ltd. has licensed in selected rights in Japan to a novel antibody from Chugai Pharmaceutical Co. Ltd.and in global markets to a Janus kinase (JAK) inhibitor developed by Astellas Pharma Inc.
In licensing to Maruho the Japanese rights to develop and market nemolizumab (CIM331) for skin disorders, Chugai has taken a further step back from its
CEO Paul Stoffels exits early to be succeeded by Henry Gosebruch, who will now consider ‘all options’ for the Belgian firm as it tries to claw back investor confidence.
As CEO Anderson backs high prices for innovative drugs in Europe
Novo Nordisk enjoyed a surprise GLP-1 agonist contracting win in the first quarter of 2025. This provided a welcome boost to its stock after it had spent the previous quarter on the back foot against rival Lilly.
